Institute for Immunology and Immune Health (I3H)
@i3h-upenn.bsky.social
Transforming routine immune profiling to power the future of medicine. I3H builds on Penn Medicine’s pioneering legacy in immunology to advance discovery across disciplines. Perelman School of Medicine, University of Pennsylvania
🔗 www.med.upenn.edu/i3h
🔗 www.med.upenn.edu/i3h
Pinned
Three weeks to go!⏳Register for the Immune Health Hackathon (Nov. 20–21). Join the Penn community for 48 hours of collaboration and discovery as teams tackle real-world challenges in immunology research. Don’t miss it—register today: i3hevents.org
Reposted by Institute for Immunology and Immune Health (I3H)
Cleanet automates doublet detection in cytometry data ft. Matei Ionita, Michelle McKeague, @markmpainter.bsky.social, Divij Mathew, Ajinkya Pattekar, Ayman Rezk, Shwetank, Damian Maseda, @ejohnwherry.bsky.social & Allison Greenplate (@i3h-upenn.bsky.social) onlinelibrary.wiley.com/doi/10.1002/...
November 11, 2025 at 6:09 PM
Cleanet automates doublet detection in cytometry data ft. Matei Ionita, Michelle McKeague, @markmpainter.bsky.social, Divij Mathew, Ajinkya Pattekar, Ayman Rezk, Shwetank, Damian Maseda, @ejohnwherry.bsky.social & Allison Greenplate (@i3h-upenn.bsky.social) onlinelibrary.wiley.com/doi/10.1002/...
Congrats to Robert H. Vonderheide, MD, DPhil, Director of the Abramson Cancer Center on receiving the 2025 Jill Rose Award—BCRF’s highest scientific honor! His pioneering work in cancer interception and immunotherapy is shaping the future of breast cancer care. https://bit.ly/3JT8QzB
November 11, 2025 at 6:20 PM
Congrats to Robert H. Vonderheide, MD, DPhil, Director of the Abramson Cancer Center on receiving the 2025 Jill Rose Award—BCRF’s highest scientific honor! His pioneering work in cancer interception and immunotherapy is shaping the future of breast cancer care. https://bit.ly/3JT8QzB
Next week's @coltonconsortium.bsky.social's seminar (Nov. 18, 11:00 a.m. ET) ft. Dr. Hafler (@yaleschoolofmed.bsky.social) is a great opportunity for #immunology and #neuroimmunology researchers. Registration is required, so be sure to RSVP to secure your spot.
Join us Nov. 18 for the Colton Consortium Virtual Speaker Series! Hear from David Hafler, MD, FANA (@yaleschoolofmed.bsky.social) a leader in #neuroimmunology, on the gut–brain axis in homeostasis and disease. Registration required: bit.ly/HaflerNov18
November 10, 2025 at 6:30 PM
Next week's @coltonconsortium.bsky.social's seminar (Nov. 18, 11:00 a.m. ET) ft. Dr. Hafler (@yaleschoolofmed.bsky.social) is a great opportunity for #immunology and #neuroimmunology researchers. Registration is required, so be sure to RSVP to secure your spot.
By tracing the evolution of adaptive immunity, J. Oriol Sunyer and his team at Penn Vet are revealing unexpected connections between fish and human immune systems—offering clues that could guide future therapies. https://bit.ly/4nOD5p7
What evolutionary and comparative immunology can teach about fish and human immune systems | Penn Today
Penn Vet’s J. Oriol Sunyer explores how studying the evolution of the immune system reveals surprising connections between fish and human immunity, and what these discoveries could mean for the develo...
bit.ly
November 10, 2025 at 5:46 PM
By tracing the evolution of adaptive immunity, J. Oriol Sunyer and his team at Penn Vet are revealing unexpected connections between fish and human immune systems—offering clues that could guide future therapies. https://bit.ly/4nOD5p7
Three weeks to go!⏳Register for the Immune Health Hackathon (Nov. 20–21). Join the Penn community for 48 hours of collaboration and discovery as teams tackle real-world challenges in immunology research. Don’t miss it—register today: i3hevents.org
October 31, 2025 at 5:14 PM
Three weeks to go!⏳Register for the Immune Health Hackathon (Nov. 20–21). Join the Penn community for 48 hours of collaboration and discovery as teams tackle real-world challenges in immunology research. Don’t miss it—register today: i3hevents.org
Penn's César de la Fuente joined Science Friday to discuss how his lab is using #AI to uncover new antibiotics hidden in ancient microorganisms—potentially offering new solutions to the global antibiotic resistance crisis. 🎧 Listen: https://www.sciencefriday.com/segments/nobel-prize-archaea/
An Off-The-Grid Nobel Win, And Antibiotics In Ancient Microbes
When the Nobel committee called, Fred Ramsdell did not pick up. Plus, searching ancient archaea for solutions to modern antibiotic resistance.
www.sciencefriday.com
October 24, 2025 at 3:55 PM
Penn's César de la Fuente joined Science Friday to discuss how his lab is using #AI to uncover new antibiotics hidden in ancient microorganisms—potentially offering new solutions to the global antibiotic resistance crisis. 🎧 Listen: https://www.sciencefriday.com/segments/nobel-prize-archaea/
E. John Wherry, PhD, Director of I3H and @penncoltoncenter.bsky.social, sat down with @inquirer.com to discuss the future of #immunology — a field just honored with a Nobel Prize — and Penn's new $376M research facility. “This is the most exciting time in my lifetime for immunology.” bit.ly/471uuKQ
Penn is expanding its research in immunology — a field just honored with a Nobel Prize
E. John Wherry, director of Penn's Colton Center for Autoimmunity, spoke with the Inquirer about the future of immunology research at Penn and the new $376 million research facility.
bit.ly
October 22, 2025 at 3:25 PM
E. John Wherry, PhD, Director of I3H and @penncoltoncenter.bsky.social, sat down with @inquirer.com to discuss the future of #immunology — a field just honored with a Nobel Prize — and Penn's new $376M research facility. “This is the most exciting time in my lifetime for immunology.” bit.ly/471uuKQ
Have you registered for the Immune Health Hackathon (Nov. 20-21)? Over the course of 48 hours, participants will work in interdisciplinary teams to tackle pressing challenges in immunology research to win cash prizes. Open to all members of the Penn community. Learn more and register: i3hevents.org
October 22, 2025 at 3:18 PM
Have you registered for the Immune Health Hackathon (Nov. 20-21)? Over the course of 48 hours, participants will work in interdisciplinary teams to tackle pressing challenges in immunology research to win cash prizes. Open to all members of the Penn community. Learn more and register: i3hevents.org
A Penn Medicine-led study revealed significant disparities in access to CAR T cell therapy for multiple myeloma among racial and ethnic minorities, despite similar treatment outcomes, highlighting the need for collaborative approaches to achieve equitable access. https://bit.ly/48OEGYz
BCMA CAR T Access Disparities Persist Among Racial/Ethnic Minority Patients With Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
A study reveals significant disparities in access to CAR T therapy for multiple myeloma among racial and ethnic minorities, despite similar treatment outcomes.
bit.ly
October 20, 2025 at 6:05 PM
A Penn Medicine-led study revealed significant disparities in access to CAR T cell therapy for multiple myeloma among racial and ethnic minorities, despite similar treatment outcomes, highlighting the need for collaborative approaches to achieve equitable access. https://bit.ly/48OEGYz
Congratulations to Leo Le Wang, MD, PhD on receiving the NIH Early Independence Award! His innovative work uses hydrogels that release healing signals to help skin regrow hair follicles—paving the way for scar-free recovery after injury or surgery. https://bit.ly/4oibmxR
Penn experts earn NIH Director’s awards for "high impact" research | Penn Medicine
The awards support unconventional approaches to major challenges in biomedical and behavioral research.
bit.ly
October 16, 2025 at 4:00 PM
Congratulations to Leo Le Wang, MD, PhD on receiving the NIH Early Independence Award! His innovative work uses hydrogels that release healing signals to help skin regrow hair follicles—paving the way for scar-free recovery after injury or surgery. https://bit.ly/4oibmxR
Congratulations to Alexander Huang, MD, assistant professor of Hematology-Oncology, who will be recognized as the 2025 Early Career Investigator Honoree at the Friends of AACR Foundation’s Party with a Purpose celebrating advances in melanoma research. https://bit.ly/4n3JAEa
Party With a Purpose 2025 Marks Progress Against Melanoma
This year, Party with a Purpose honors melanoma researchers Lynn Schuchter and Alexander Huang, and humanitarian honoree Patricia Wellenbach.
bit.ly
October 15, 2025 at 3:50 PM
Congratulations to Alexander Huang, MD, assistant professor of Hematology-Oncology, who will be recognized as the 2025 Early Career Investigator Honoree at the Friends of AACR Foundation’s Party with a Purpose celebrating advances in melanoma research. https://bit.ly/4n3JAEa
Congratulations to Janis Burkhardt, PhD, on her appointment as Associate Dean for Postdoctoral Research Training and Director of Biomedical Postdoctoral Programs (BPP) at the University of Pennsylvania. Learn more about her experience and new role: https://bit.ly/48kFEeL
October 14, 2025 at 1:09 PM
Congratulations to Janis Burkhardt, PhD, on her appointment as Associate Dean for Postdoctoral Research Training and Director of Biomedical Postdoctoral Programs (BPP) at the University of Pennsylvania. Learn more about her experience and new role: https://bit.ly/48kFEeL
Researchers led by César de la Fuente have developed new peptides that fight drug-resistant “superbugs” by breaking down bacterial cells and activating immune defenses — a breakthrough made possible by Penn’s cross-disciplinary collaboration. Learn more: https://bit.ly/3KAKH0S
Uncovering new antibiotics with AI | Penn Today
César de la Fuente leverages machine learning to accelerate the discovery of lifesaving drugs and help reduce antibiotic resistance, a rising global health problem.
penntoday.upenn.edu
October 13, 2025 at 6:55 PM
Researchers led by César de la Fuente have developed new peptides that fight drug-resistant “superbugs” by breaking down bacterial cells and activating immune defenses — a breakthrough made possible by Penn’s cross-disciplinary collaboration. Learn more: https://bit.ly/3KAKH0S
Penn virologist, Beatrice Hahn, recalls her collaboration with Jane Goodall and their work to uncover the origins of HIV. "She was an excellent scientist [...] I think she changed a number of people by simply educating them in an open and honest way.” https://bit.ly/437e3Km
On collaborating with Jane Goodall | Penn Today
Penn virologist Beatrice Hahn recalls her research partnership with Jane Goodall and their work to uncover the origins of HIV.
bit.ly
October 11, 2025 at 8:11 PM
Penn virologist, Beatrice Hahn, recalls her collaboration with Jane Goodall and their work to uncover the origins of HIV. "She was an excellent scientist [...] I think she changed a number of people by simply educating them in an open and honest way.” https://bit.ly/437e3Km
New @pennmedicine.bsky.social research identifies a potential targeted treatment for Sweet’s syndrome—a rare, painful skin disease—by breaking a cycle of rogue immune cells that drive inflammation. A discovery that could one day replace steroids. www.pennmedicine.org/news/mechani...
October 10, 2025 at 2:58 PM
New @pennmedicine.bsky.social research identifies a potential targeted treatment for Sweet’s syndrome—a rare, painful skin disease—by breaking a cycle of rogue immune cells that drive inflammation. A discovery that could one day replace steroids. www.pennmedicine.org/news/mechani...
Congrats to Dr. Fajgenbaum on making the 2025 #TIME100Next list! Co-founder of Every Cure, Castleman Disease Collaborative Network, and Penn’s Center for Cytokine Storm Treatment & Laboratory, he’s recognized for his research on repurposing existing drugs for rare diseases. https://bit.ly/4q16bE3
David Fajgenbaum Is on the 2025 TIME100 Next
Find out why David Fajgenbaum is on this year’s list
time.com
October 10, 2025 at 1:03 PM
Congrats to Dr. Fajgenbaum on making the 2025 #TIME100Next list! Co-founder of Every Cure, Castleman Disease Collaborative Network, and Penn’s Center for Cytokine Storm Treatment & Laboratory, he’s recognized for his research on repurposing existing drugs for rare diseases. https://bit.ly/4q16bE3
The latest pub from I3H—led by Matei Ionita—introduces Cleanet, the first multivariate method to detect doublets in #cytometry, with the aim to automate data analysis workflows and lead to more robust and scalable analysis results for #immunology studies. https://bit.ly/3KBaFkV
Cleanet: Robust Doublet Detection in Cytometry Data Based on Protein Expression Patterns
Flow and mass cytometry experiments are essential for profiling immune cells at single-cell resolution. Better understanding of human immunology increasingly involves analyzing studies at the scale o...
bit.ly
October 9, 2025 at 7:53 PM
The latest pub from I3H—led by Matei Ionita—introduces Cleanet, the first multivariate method to detect doublets in #cytometry, with the aim to automate data analysis workflows and lead to more robust and scalable analysis results for #immunology studies. https://bit.ly/3KBaFkV
Early findings from @pennmedicine.bsky.social and @cincychildrens.bsky.social suggest a new vaccine may prevent allergens from triggering harmful immune reactions and inflammation—"a potential breakthrough for millions of people worldwide who suffer from life-threatening allergies." spr.ly/6018AUcJO
October 7, 2025 at 6:14 PM
Early findings from @pennmedicine.bsky.social and @cincychildrens.bsky.social suggest a new vaccine may prevent allergens from triggering harmful immune reactions and inflammation—"a potential breakthrough for millions of people worldwide who suffer from life-threatening allergies." spr.ly/6018AUcJO
Registration is open for the Immune Health Hackathon (Nov. 20-21)! Over the course of 48 hours, participants will work in interdisciplinary teams to tackle pressing challenges in immunology research! Open to all members of the Penn community. Register: i3hevents.org
October 1, 2025 at 7:42 PM
Registration is open for the Immune Health Hackathon (Nov. 20-21)! Over the course of 48 hours, participants will work in interdisciplinary teams to tackle pressing challenges in immunology research! Open to all members of the Penn community. Register: i3hevents.org
Earlier this month, Dr. Carl June was selected for the inaugural Broermann Medical Innovation Award for his pioneering work on CAR-T immunotherapy. He spoke with the @inquirer.com recently about the future of CAR-T research.
Penn’s CAR-T pioneer Carl June talks about the future of his award-winning work to train the body to fight cancer
The Penn scientist spoke with the Inquirer about his lab’s latest research and the future of CAR-T.
www.inquirer.com
September 30, 2025 at 6:43 PM
Earlier this month, Dr. Carl June was selected for the inaugural Broermann Medical Innovation Award for his pioneering work on CAR-T immunotherapy. He spoke with the @inquirer.com recently about the future of CAR-T research.
Registration is open! Oct 3–4 @ PA Convention Center, Philadelphia. The 2nd Annual Advancing Precision Medicine Conference: "Advances in Precision Oncology: From Genomics to Targeted Therapies" is free and in person. Ft. Nobel Laureate Dr. Kaelin. https://bit.ly/48odQpH
APM Annual Conference Philadelphia, PA - Advancing Precision Medicine
Advancing Precision Medicine Conference and Exhibition will take place at the Philadelphia Convention Center in November 1-2, 2024.
www.advancingprecisionmedicine.com
September 20, 2025 at 4:02 PM
Registration is open! Oct 3–4 @ PA Convention Center, Philadelphia. The 2nd Annual Advancing Precision Medicine Conference: "Advances in Precision Oncology: From Genomics to Targeted Therapies" is free and in person. Ft. Nobel Laureate Dr. Kaelin. https://bit.ly/48odQpH
At 3600 Civic Center Blvd, E. John Wherry, PhD welcomed Good Morning Philadelphia to Penn Medicine's new hub for hundreds of researchers in immune health, infectious disease, population health data sciences, and others engaged in cross-disciplinary collaboration. https://bit.ly/4mmwd1w
September 19, 2025 at 1:15 PM
At 3600 Civic Center Blvd, E. John Wherry, PhD welcomed Good Morning Philadelphia to Penn Medicine's new hub for hundreds of researchers in immune health, infectious disease, population health data sciences, and others engaged in cross-disciplinary collaboration. https://bit.ly/4mmwd1w
⏱️ Every minute in the United States, someone needs a blood transfusion because of their period. Penn’s Dr. Kathleen O’Neill is developing an mRNA therapy to treat abnormal uterine bleeding and uncover its causes—a potential breakthrough for menstrual health and #mRNA technology. bit.ly/4n8rGkB
September 17, 2025 at 6:55 PM
⏱️ Every minute in the United States, someone needs a blood transfusion because of their period. Penn’s Dr. Kathleen O’Neill is developing an mRNA therapy to treat abnormal uterine bleeding and uncover its causes—a potential breakthrough for menstrual health and #mRNA technology. bit.ly/4n8rGkB
Last week, Penn Medicine leaders cut the ribbon on a new home for #immunology research. The eight-story "overbuild" at 3600 Civic Center Blvd will house I3H, #ImmuneHealth, @penncoltoncenter.bsky.social, and related areas to foster interdisciplinary collaboration.
▶️ Watch: youtu.be/Ryv2AxPtb_E?...
▶️ Watch: youtu.be/Ryv2AxPtb_E?...
Building Upon Excellence: Penn’s New Collaborative Research Hub
YouTube video by Penn Medicine
youtu.be
September 8, 2025 at 6:19 PM
Last week, Penn Medicine leaders cut the ribbon on a new home for #immunology research. The eight-story "overbuild" at 3600 Civic Center Blvd will house I3H, #ImmuneHealth, @penncoltoncenter.bsky.social, and related areas to foster interdisciplinary collaboration.
▶️ Watch: youtu.be/Ryv2AxPtb_E?...
▶️ Watch: youtu.be/Ryv2AxPtb_E?...
Healthy blood cells can live without ARHGAP45—but acute myeloid leukemia cells can’t. 🩸 Junwei Shi, PhD (Associate Professor of Cancer Biology) and team show a CAR T + CDC42 inhibition strategy could target AML with minimal side effects. bit.ly/45OyXQu
September 5, 2025 at 7:42 PM
Healthy blood cells can live without ARHGAP45—but acute myeloid leukemia cells can’t. 🩸 Junwei Shi, PhD (Associate Professor of Cancer Biology) and team show a CAR T + CDC42 inhibition strategy could target AML with minimal side effects. bit.ly/45OyXQu